NDAORALTABLET
Approved
Oct 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
18
Data completeness
4/8 — Partial
VELSIPITY (etrasimod) by Pfizer. Approved for ulcerative colitis, crohn's disease, pouchitis and 4 more indications. First approved in 2023.
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VELSIPITY (etrasimod) is an oral small-molecule sphingosine-1-phosphate (S1P) receptor modulator approved in October 2023 for multiple immune-mediated inflammatory conditions. The drug works by modulating lymphocyte trafficking to reduce pathogenic immune responses in the gut and skin. It is indicated for ulcerative colitis, Crohn's disease, pouchitis, immune checkpoint inhibitor-related colitis, alopecia areata, atopic dermatitis, and eosinophilic esophagitis.
Growth10.1 years to LOE
Recent launch in growth phase with Pfizer's commercial muscle and large competitive indication base signals expanding team hiring for field and market-access roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (7)
Worked on VELSIPITY at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.